<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503568</url>
  </required_header>
  <id_info>
    <org_study_id>20020225</org_study_id>
    <secondary_id>SCCC-2002041</secondary_id>
    <secondary_id>WIRB-20050969</secondary_id>
    <nct_id>NCT00503568</nct_id>
    <nct_alias>NCT00247065</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy</brief_title>
  <official_title>Novel Tumor Vaccine gp96-Ig Fusion Protein in Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective&#xD;
      immune response to kill non-small cell lung cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the effects of gp96-Ig vaccine therapy in treating&#xD;
      patients with stage III, stage IV, or relapsed non-small cell lung cancer treated with&#xD;
      first-line chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Goals:&#xD;
&#xD;
      - to evaluate the safety and induction of anti-tumor immunity by administration of an&#xD;
      immunogenic human tumor cell vaccine, and assess immune response in relation to clinical&#xD;
      outcome.&#xD;
&#xD;
      Primary Aim:&#xD;
&#xD;
      - to evaluate the safety of administering a heat shock protein gp96-Ig-secreting allogeneic&#xD;
      tumor cell-vaccine (gp96-Ig vaccine) in patients with advanced NSCLC.&#xD;
&#xD;
      Secondary Aims:&#xD;
&#xD;
        -  to study the immune response to vaccination,&#xD;
&#xD;
        -  to monitor clinical responses and&#xD;
&#xD;
        -  to recommend a dose-schedule combination for further testing in an initial Phase II&#xD;
           trial of vaccine efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6, 12, 18, 24, and 36 months post enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic response: CD8, CD4 and NK response</measure>
    <time_frame>Baseline, Day 1 Week1, Day 1 Week 13, Day 1 Week 19</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>DS-1: gp96-ig Dose Schedule 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10^7 cells bi-weekly, maximum 9 vaccines/patient;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-2: gp96-ig Dose Schedule 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10^7 cells weekly, maximum 18 vaccines/patient;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-3: gp96-ig Dose Schedule 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10^7 cells twice weekly, maximum 36 vaccines/patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad100-gp96Ig-HLA A1</intervention_name>
    <description>Dose Schedule 1 (DS-1): 4x10^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10^7 cells twice weekly, maximum 36 vaccines/patient</description>
    <arm_group_label>DS-1: gp96-ig Dose Schedule 1</arm_group_label>
    <arm_group_label>DS-2: gp96-ig Dose Schedule 3</arm_group_label>
    <arm_group_label>DS-3: gp96-ig Dose Schedule 3</arm_group_label>
    <other_name>gp96-vaccine</other_name>
    <other_name>gp96-Ig and HLA A1 transfected Non-Small Cell Lung Cancer cell line</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histologically confirmed NSCLC (squamous, adeno-, large cell anaplastic,&#xD;
             bronchoalveolar, and non-small cell carcinoma NOS): stage IIIB with malignant pleural&#xD;
             effusion, stage IV, or recurrent disease.&#xD;
&#xD;
          -  At least one site of bi-dimensionally measurable disease.&#xD;
&#xD;
          -  Metastasis if present and treated must be stable by CT scan or MRI for at least 8&#xD;
             weeks.&#xD;
&#xD;
          -  Patient must have received and failed at least one line of chemotherapy.&#xD;
&#xD;
          -  Age &gt;= 18 years.&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  Life expectancy &gt;= 3 months.&#xD;
&#xD;
          -  Laboratory parameters:&#xD;
&#xD;
               -  Hemoglobin levels &gt;= 10.0 (transfusions allowed if necessary).&#xD;
&#xD;
               -  ANC &gt;= 1,500.&#xD;
&#xD;
               -  Platelets &gt;= 100k.&#xD;
&#xD;
               -  Creatinine clearance &gt;= 50 ml/min.&#xD;
&#xD;
               -  Total and direct bilirubin: &lt; 2.5 X upper institution limit for normal.&#xD;
&#xD;
               -  Liver function tests: AST, ALT, and AlkP &lt; 2.5 X upper institution limit for&#xD;
                  normal.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Autopsy consent - although not a requirement for study entry, patients who consent to&#xD;
             participate in study will be made aware of the critical importance of a post-mortem&#xD;
             examination in the event of the patient's death after receiving therapy with this&#xD;
             experimental vaccine. Therefore, pre-treatment written agreement to autopsy will be&#xD;
             sought from the patient, or verbal agreement to autopsy will be sought in the presence&#xD;
             of the next of kin or other family members.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Active or symptomatic cardiac disease such as congestive heart failure, angina&#xD;
             pectoris or recent myocardial infarction. Patients with history of these conditions&#xD;
             who are stable taking cardiac medications will also be excluded.&#xD;
&#xD;
          -  Pregnant or lactating women (negative test for pregnancy is required of women of&#xD;
             childbearing potential).&#xD;
&#xD;
          -  Known HIV infection.&#xD;
&#xD;
          -  Uncontrolled or untreated brain or spinal cord metastases.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Concomitant steroid or other immunosuppressive therapy.&#xD;
&#xD;
          -  Other active malignancies present within the past three years, except for basal and/or&#xD;
             squamous cell carcinoma(s) or in situ cervical cancer.&#xD;
&#xD;
          -  Alcohol or chemical abuse.&#xD;
&#xD;
          -  Meningeal carcinomatosis.&#xD;
&#xD;
          -  Chemotherapy, radiation therapy, or other anti-tumor therapy during the last four&#xD;
             weeks.&#xD;
&#xD;
          -  Prior biologic response modifier therapy.&#xD;
&#xD;
          -  Refusal in fertile men or women to use effective birth control measures during and for&#xD;
             six months after the completion of treatment on study.&#xD;
&#xD;
          -  Immune deficiency syndromes, including the following: rheumatoid arthritis, systemic&#xD;
             lupus erythematosus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis,&#xD;
             glomerulonephritis.&#xD;
&#xD;
          -  Compromised lung function:&#xD;
&#xD;
               -  FeV1 &lt; 30% of the predicted value, or&#xD;
&#xD;
               -  DLCO &lt; 30% of the predicted value, or&#xD;
&#xD;
               -  PCO2 &gt; 45 mmHg.&#xD;
&#xD;
          -  Any patient enrolled on study whose respiratory symptoms have experienced marked&#xD;
             deterioration not related to a known cause, such as pneumonia, congestive heart&#xD;
             failure, or pulmonary embolism, will have a repeat PFT evaluation, and if the above&#xD;
             parameter values for FeV1, DLCO, or PCO2 are seen, will be excluded from further&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis E. Raez, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004 Jul 15;22(14):2800-7.</citation>
    <PMID>15254047</PMID>
  </reference>
  <results_reference>
    <citation>Raez LE, Podack ER, CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Advances in Lung Cancer 2(1): 9-18, 2013 doi:10.4236/alc.2013.21002</citation>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

